Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accrued and other liabilities, current and non-current | 24,938 | 1,268 |
| Net cash provided by operating activities | 16,771 | 49,067 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (2,729) | (161) |
| Proceeds from sales and maturities of marketable securities | 119,312 | 205,536 |
| Purchases of marketable securities | (141,283) | (138,419) |
| Net cash (used in) provided by investing activities | (24,700) | 66,956 |
| Cash flows from financing activities: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's capex?
- Corcept Therapeutics (CORT) reported capex of $2.53M in Q2 2026.
- How has Corcept Therapeutics's capex changed year-over-year?
- Corcept Therapeutics's capex increased by 4335.1% year-over-year, from $57K to $2.53M.
- What is the long-term trend for Corcept Therapeutics's capex?
- Over 4 years (2021 to 2025), Corcept Therapeutics's capex has grown at a -18.1% compound annual growth rate (CAGR), from $469K to $211K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Corcept Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude